Corrections

Gabapentin induced cholestasis

BMJ 2002; 325 doi: https://doi.org/10.1136/bmj.325.7371.1006 (Published 02 November 2002) Cite this as: BMJ 2002;325:1006

In the Drug Point by Charles E Richardson and colleagues (21 September, p 635), gabapentin was reported to be an unlicensed indication for the management of diabetic neuropathy. The authors have now clarified, however, that gabapentin has in fact been licensed for the treatment of neuropathic pain for over two years.

Footnotes

View Abstract